Panacos reiterated at outperform by RBC

Panacos Pharmaceuticals Inc. was reiterated at outperform, speculative risk, by RBC Capital Markets analyst Jason Kantor after Panacos reported third-quarter results with revenue of $30,000 versus RBC's expectation of $40,000, which generally consists of small research funding. The analyst added that net loss was $8 million versus a forecast of $9 million and earnings per share was a loss of $0.13 versus an expectation of $0.19. Shares of the Watertown, Mass.-based biotechnology company were down 15cents, or 2.33%, at $6.29, on volume of 710,042 shares versus the three-month running average of 514,562 shares. (Nasdaq: PANC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.